Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitorsZhaozhong J Jia, Yanhong Wu, Wenrong Huang, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 3, 2019
CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the BloodBin N Zhao, James J Campbell, Catherina L Salanga, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2019
Efficacy of Chemokine Receptor Inhibition in Treating IL-36α-Induced Psoriasiform InflammationJames J Campbell, Karen Ebsworth, Linda S Ertl, et al.Plos One|October 22, 2016
Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPirow Bekker, Daniel Dairaghi, Lisa Seitz, et al.Plos One|January 5, 2019
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical StudyPirow Bekker, Daniel Dairaghi, Lisa Seitz, et al.International Journal of Cancer|December 27, 2017
Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer modelsYong Luo, Abul Kalam Azad, Styliani Karanika, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|May 17, 2003
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitorsUma Sinha, Pei Hua Lin, Susan T Edwards, et al.Bioorganic & Medicinal Chemistry Letters|July 28, 2006
Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivoJeffrey R Spencer, Martin Sendzik, Jason Oeh, et al.Plos One|March 22, 2018
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)Zhenhua Miao, Linda S Ertl, Dale Newland, et al.American Journal of Physiology. Gastrointestinal and Liver Physiology|February 9, 2018
CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver diseaseRichard Parker, Christopher J Weston, Zhenhua Miao, et al.Pageof 4